Antiretroviral-based HIV prevention strategies for women

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 10, 2010, Pages 1177-1186

  Chirenje, Z Mike ^a   Marrazzo, Jeanne ^b   Parikh, Urvi M ^c  

^a UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

antiretroviral agents; biological plausibility; chemoprophylaxis; post exposure prophylaxis; pre exposure prophylaxis; topical microbicides

Indexed keywords

ANTIRETROVIRUS AGENT; CARRAGEENAN; CELLULOSE SULFATE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MICROBICIDE; PLACEBO; RALTEGRAVIR; SAVY; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; MOTHER CHILD RELATION; MULTIPLE CYCLE TREATMENT; PREVALENCE; PRIMATE; REVIEW; RISK REDUCTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SINGLE DRUG DOSE; STRATEGIC PLANNING; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADULT; AFRICA SOUTH OF THE SAHARA; ANIMALS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HIV INFECTIONS; HUMANS; MACACA; MALE; MICE; PREVALENCE; SEXUALLY TRANSMITTED DISEASES, VIRAL; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 77958178127     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.79     Document Type: Review

References (49)

1. Elias C, Coggins C. Female-controlled methods to prevent sexual transmission of HIV. AIDS 10, S43-S51 (1996).
2. Susser I, Stein Z. Culture, sexuality, and women's agency in the prevention of HIV/AIDS in southern Africa. Am. J. Public Health 90, 1042-1048 (2000).
3. Rerks-Ngarm S, Pitusittithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
4. Cohen J. Is an effective HIV vaccine feasible? Science 309(5731), 99 (2005).
5. Bailey RC, Moses S, Parker CB et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomized controlled trial. Lancet 369, 643-676 (2007).
6. Auvert B. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the NNRS 1265 trial. PLoS Med. 2(11), e298 (2005).
7. Gray RH, Kigoz G, Serwadda D et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomized trial. Lancet 369, 657-666 (2007).
8. Van Damme L, Ramjee G, Alary M, Vuylsteke B. Effectiveness of Col-1492, a nonoxynol-9 vaginal gel, on HIV transmisison in female sex workers: a randomized controlled trial. Lancet 360, 917-927 (2002).
9. Hillier S, Moench T, Shattock R et al. In vitro and in vivo: the story of nonoxynol 9. J. Acquir. Immune Defic. Syndr. 39, 1-8 (2005).
10. Van Damme L, Govinden R, Mirembe FM et al. Lack of effectiveness of cellulose sulphate gel for prevention of vagina HIV transmission N. Engl. J. Med. 359, 463-472 (2008).
11. Karim SA, Richardson B, Ramjee G et al. Safety and effectiveness of buffer gel and 0.5% Pro 2000 gel for prevention of HIV infection in women: results of HPTN 035 microbicide trial. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montréal, Canada, February 8-11 2009.
12. McCormack S, Ramjee G, Kamila A et al. PRO200 vaginal gel for HIV prevention: results of the MDP301 Phase III randomized microbial trial. Lancet (2010) (In press).
13. Van Rompay KK, Marthas ML, Ramos RA et al. Simian immunodefciency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection. Antimicrob. Agents Chemother. 36, 2381-2386 (1992).
14. Tsai C, Follis KE, Sabo A et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 270, 1197-1199 (1995).
15. Subbarao S, Otten RA, Ramos A et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodefciency virus in macaques given multiple virus challenges. J. Infect. Dis. 194, 904-911 (2006).
16. Cranage M, Sharpe S, Herrera C et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 5, e157 (2008).
17. Parikh UM, Dobard C, Sharma S et al. Complete protection from repeated vaginal simian-human immunodefciency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol. 83, 10358-10365 (2009). •• Demonstration of the biological plausibility of complete protection of viral infection by topical gel in a macaque model.
18. Chenine AL, Siddappa NB, Kramer VG et al. Relative transmissibility of an R5 clade C simian-human immunodefciency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes. J. Infect. Dis. 201, 1155-1163 (2010).
19. Tsai C, Emau P, Follis KE et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodefciency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J. Virol. 72, 4265-4273 (1998).
20. + T cells but fails to prevent disease. J. Virol. 83, 7099-7108 (2009).
21. Garcia-Lerma JG, Otten RA, Qari SH et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 5, e28 (2008).
22. Garcia-Lerma J, Cong M, Mitchell J et al. Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci. Transl. Med. 2, 14ra14 (2010).
23. Denton PW, Estes JD, Sun Z et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5, e16 (2008). • Timing of pre-exposure prophylaxis and adequate dose of drug in relation to exposure to viral inoculum are critical for maximum effcacy.
24. García-Lerma JG, Paxton L, Kilmarx PH, Heneine W. Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol. Sci. 31, 74-81 (2010).
25. Pereira AS, Kashuba AD, Fiscus SA et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J. Infect. Dis. 180, 2039-2043 (1999).
26. Min SS CA, Rezk N, Cu-Uvin S et al. Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J. Acquir. Immune Defc. Syndr. 37(5), 1577-1580 (2004).
27. Dumond JB, Yeh RF, Patterson KB et al. Anti retroviral drug exposure in the female genital tract: implications for oral pre-and post-exposure prophylaxis. AIDS 21, 1899-1907 (2007).
28. Vourvahis M, Tappouni HL, Patterson KB et al. The pharmacokinetics and viral activity of tenofovir in the male genital tract. J. Acquir. Immune Defc. Syndr. 47, 329-333 (2008).
29. Peterson L, Taylor D, Roddy R, Belai G, Phillips P. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a Phase 2, double blind, randomized, placebo controlled trial. PLoS Clin. Trials 2(5), e27 (2007).
30. Karim QA, Karim SA, Frolich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996), 1168-1174 (2010).
31. Smith DK, Grohskopf LA, Black RJ et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U. S. Department of Health and Human Services. MMWR Recomm. Rep. 54 (RR02), 1-20 (2005).
32. Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. N. Engl. J. Med. 361, 1768-1777 (2009).
33. Jones A, Talameh J, Patterson K et al. First-dose and steady-state pharmacokinetics (PK) of raltegravir (RAL) in the genital tract (GT) of HIV uninfected women. Presented at: 10th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands, 15-17 April 2009.
34. th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19-22 July 2009.
35. Granich R, Gilks C, Dye C, De Cock K, Williams B. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373, 48-57 (2009).
36. Granich R, Crowley S, Vitoria M et al. Highly active antiretroviral treatment for the prevention of HIV transmission. J. Int. AIDS Soc. 13, 1 (2010). • Guidelines to antiretroviral therapy initiation that has Significant impact in reducing HIV transmission.
37. Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst. Rev. 3, CD008272 (2010).
38. Auvert B, Males S, Puren A et al. Can highly active antiretroviral therapy reduce the spread of HIV? A study in a township of South Africa. J. Acquir. Immune Defc. Syndr. 36, 613-621 (2004).
39. Das-Douglas M, Chu P, Santos G-M et al. Decreases in community viral load are associated with a reduction in new HIV diagnoses in San Francisco. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010 (Abstract 33). •• Evidence of decreased community viral load associated with a reduction in new HIV infections.
40. Kalichman S, Eaton L, Cherry C. Sexually transmitted infectious and infectiousness beliefs among people living with HIV/AIDS: implications for HIV treatment as prevention. HIV Med. 11(8), 502-509 (2010).
41. Taber R, Rajakumar PA, Fuller DH et al. Effects of monotherapy with (R)-9-(2-phonsphonylmethoxypropyl) adenine (PMPA) on the evolution of a primary Simian immunodefciency virus (SIV) isolate. Virology 354, 116-131 (2006).
42. Van Rompay K K A, Johnson JA, Blackwood EJ et al. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology 4, 25 (2007).
43. Miller C, Shattock R. Target cells in vaginal HIV transmission. Microbes Infect. 5, 59-67 (2003).
44. Fleming TR, Richardson BA. Some design issues in trials of microbicides for prevention of HIV infection J. Infect. Dis. 190, 666-674 (2004).
45. Basic design features: size, duration and type of trials and choice of control group. In: Methodological Challenges in Biological HIV Prevention Trials. Lagakos SW, Gable AR (Eds). Institute of Medicine of the National Academies, The National Academic Press, Washington, DC, USA, 69-87 (2008).
46. Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 flm to reduce male-to-female transmission of sexually transmitted diseases. N. Engl. J. Med. 339(8), 504-510 (1998).
47. Feldblum PJ, Adeiga A, Bakare R et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 3(1), e1474 (2008).
48. Halpern V, Ogunsola F, Obunge O et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS ONE 3(11), e3784 (2008).
49. Skoler-Karpoff S, Ramjee G, Ahmed K et al. Effcacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebocontrolled trial. Lancet 372(9654), 1977-1987 (2008).